Story perspectives

Eli Lilly's Orforglipron Shows Promise for Diabetes Treatment

10/16/2025

Summary

Story summary

Eli Lilly's orforglipron achieved up to 2.1% A1C reduction in two Phase 3 trials for type 2 diabetes when combined with insulin glargine.
The trials showed weight loss and improved cardiovascular risk factors.
Lilly plans to submit orforglipron for regulatory approval in 2026, with an obesity submission due by end-2025.
Despite earlier skepticism, Lilly remains optimistic about orforglipron's potential in the diabetes market.
Analysts expect robust uptake.

1 of 1

Story summary

Eli Lilly's orforglipron achieved up to 2.1% A1C reduction in two Phase 3 trials for type 2 diabetes when combined with insulin glargine.
The trials showed weight loss and improved cardiovascular risk factors.
Lilly plans to submit orforglipron for regulatory approval in 2026, with an obesity submission due by end-2025.
Despite earlier skepticism, Lilly remains optimistic about orforglipron's potential in the diabetes market.
Analysts expect robust uptake.